SCHEMBL3015649

SCHEMBL3015649

O=S(=O)(c1cccc(C(F)(F)F)c1)C1CCN(c2nc(-c3ccc(Cl)cc3Cl)cs2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 3/20 0.51
CTSS P25774 1/20 0.45
KDM1A O60341 1/20 0.43
NPSR1 Q6W5P4 1/20 0.42
RAB9A P51151 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
RAF1 P04049 1/20 0.41
BRAF P15056 1/20 0.41
NPC1 O15118 2/20 0.41
CYP1A2 P05177 2/20 0.40
CYP2C19 P33261 2/20 0.40
HTT P42858 2/20 0.40
KDM4E B2RXH2 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
EGFR P00533 1/20 0.39
LMNA P02545 1/20 0.39
CYP3A4 P08684 1/20 0.39
MAPT P10636 1/20 0.39
CYP2C9 P11712 1/20 0.39
MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3003356 0.90 AR (0.57) ARKDM1ANPSR1RAB9ASMN1; SMN2
SCHEMBL3015599 0.88 AR (0.53) ARCTSSNPSR1RAB9ASMN1; SMN2
SCHEMBL3009367 0.88 KDM1A (0.56) ARCTSSKDM1ARAB9ASMN1; SMN2
SCHEMBL3008360 0.87 AR (0.52) ARCTSSKDM1ARAB9ASMN1; SMN2
SCHEMBL3019325 0.87 AR (0.52) ARNPSR1RAB9ASMN1; SMN2NPC1
SCHEMBL3006979 0.86 AR (0.53) ARKDM1ANPSR1RAB9ASMN1; SMN2
SCHEMBL3010933 0.86 AR (0.53) ARKDM1ASMN1; SMN2RAF1BRAF
SCHEMBL3011795 0.85 AR (0.50) ARCTSSKDM1ARAB9ASMN1; SMN2
SCHEMBL3017157 0.85 AR (0.60) ARNPSR1RAB9ASMN1; SMN2NPC1
SCHEMBL3021277 0.85 AR (0.60) ARNPSR1RAB9ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885CTSS 106/4885KDM1A 3548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.